BUSINESSCNBC TOP
Weight loss drug maker sinks 25% after new safety data spooks investors
A weight loss drug maker's stock declined 25% after new safety data raised concerns among investors. The experimental drug met its key targets, but analysts are worried about its commercial potential due to side effects.
Related Signal
Adjacent reporting
- Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death
- Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
- Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
- Hims & Hers plummets 15% after first-quarter loss, weak earnings guidance
- People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says
- Horrific new 'Darth Vader' Ozempic side effect: DR SHEILA fears super-powered weight loss drugs are triggering unimaginable conditions... and all because of this simple mistake